ZIVO Bioscience Enters Large-Scale Manufacturing Partnership with Cyanotech Corporation to Produce Zivolife™ Algal Biomass
Zivo Bioscience, Inc. (OTCQB: ZIVO), a research-driven biotech and agtech innovator specializing in therapeutic, medicinal, and nutritional products derived from proprietary algal cultures, has announced a significant step forward in its commercialization strategy. The company has entered into a manufacturing agreement with Cyanotech Corporation, a globally recognized leader in large-scale microalgae cultivation. Under this partnership, Cyanotech will be responsible for growing, cultivating, and processing ZIVO’s proprietary algal biomass to support the company’s Zivolife™ product line.
This agreement marks a critical milestone for ZIVO as it transitions from research and development into commercial readiness. With Zivolife™ positioned for applications across animal health, human nutrition, and functional ingredient markets, the company is preparing to meet growing demand from both existing collaborators and potential global partners. Establishing a reliable and scalable manufacturing infrastructure is a key component of this strategy, and the partnership with Cyanotech is expected to play a central role in enabling that transition.
ZIVO’s Zivolife™ platform is built on the company’s proprietary algal strains, particularly Klebsormidium flaccidum, which has demonstrated promising attributes for use in a wide range of health and nutrition applications. The company has been focused on unlocking the potential of this algae-derived biomass, exploring its benefits in areas such as immune modulation, anti-inflammatory activity, and overall health support. As interest in natural and sustainable bio-based ingredients continues to grow globally, ZIVO aims to position Zivolife™ as a differentiated offering within both established and emerging markets.
The collaboration with Cyanotech provides ZIVO with access to a world-class production partner that brings decades of experience and infrastructure to the table. Founded in 1984, Cyanotech has been a pioneer in the commercialization of microalgae, making it one of the most experienced companies in the sector. Its operations are based on the Kailua-Kona Coast of Hawaii’s Big Island, where it operates a 96-acre production facility within the Natural Energy Laboratory of Hawaii Authority (NELHA). This site is widely regarded as one of the largest and most advanced microalgae production facilities in the world.
The location of Cyanotech’s operations offers several natural advantages that are particularly well-suited for microalgae cultivation. The region benefits from abundant year-round sunlight, clean air, and access to pristine lava-filtered seawater, all of which contribute to optimal growing conditions. Additionally, the site is located within a designated biosecure zone, minimizing the risk of contamination and ensuring consistent production quality. These environmental factors enable continuous, 12-month production cycles, a critical capability for meeting large-scale commercial demand.
Cyanotech’s expertise extends across multiple species of microalgae, including commercially established strains such as Spirulina and Haematococcus. The company has successfully scaled production of these organisms for use in dietary supplements, nutraceuticals, and food applications, demonstrating its ability to translate scientific innovation into commercially viable products. With the addition of ZIVO’s proprietary Klebsormidium flaccidum to its portfolio, Cyanotech will apply its proven cultivation techniques and operational processes to support the production of Zivolife™.
Another key strength of Cyanotech lies in its commitment to quality and regulatory compliance. The company operates under current Good Manufacturing Practices (cGMP), ensuring that its production processes meet stringent industry standards. It also employs rigorous third-party quality control measures to maintain product consistency and safety. Furthermore, Cyanotech’s microalgae products have achieved GRAS (Generally Recognized as Safe) status for food use, reflecting a strong track record of regulatory alignment. These capabilities are expected to be instrumental in supporting ZIVO as it seeks to bring its products to market across multiple regulatory jurisdictions.
From a commercial perspective, Cyanotech has demonstrated consistent growth, with recent financial results reflecting approximately 20% year-over-year revenue increases. This track record underscores the company’s ability to operate at scale while maintaining efficiency and quality, making it a reliable partner for organizations like ZIVO that are entering the commercialization phase.
According to John Payne, Chief Executive Officer and Chairman of Zivo Bioscience, the agreement represents a transformational moment for the company. He emphasized that securing a partner with Cyanotech’s level of expertise and production capacity provides ZIVO with the infrastructure needed to confidently respond to global demand for Zivolife™. Payne also highlighted the importance of building a dependable supply chain, noting that it is a critical step toward enabling initial commercial revenues and supporting long-term growth.
The establishment of a robust supply chain is particularly important for companies operating in the biotech and agtech sectors, where scaling production from laboratory to commercial volumes can present significant challenges. By leveraging Cyanotech’s existing infrastructure, ZIVO can accelerate this process, reducing the time and capital required to bring its products to market. This approach allows the company to focus more on product development, market expansion, and partnership opportunities.
From Cyanotech’s perspective, the partnership represents an opportunity to expand its portfolio and collaborate with an innovative company that is developing a novel class of algal-based products. Matthew Custer, President and Chief Executive Officer of Cyanotech Corporation, expressed enthusiasm about the collaboration, noting that the agreement provides ZIVO with scalable production capacity to support initial commercial volumes while also offering the flexibility to expand as demand grows. He also highlighted the unique qualities of ZIVO’s proprietary algal biomass, describing it as a compelling product with strong potential appeal in consumer and commercial markets.
The scalability of production is a crucial element of the agreement. As ZIVO continues to develop its commercial pipeline and secure partnerships, demand for Zivolife™ products is expected to increase. The ability to ramp up production efficiently will be essential for meeting this demand without compromising quality or consistency. Cyanotech’s established infrastructure and operational expertise position it well to support this growth trajectory.
Beyond immediate production capabilities, the partnership also reflects broader trends within the biotechnology and nutrition industries. There is increasing interest in sustainable, plant-based, and bio-derived ingredients as consumers and companies alike seek alternatives to traditional sources. Microalgae, in particular, have gained attention for their versatility, nutritional value, and relatively low environmental impact compared to conventional agricultural products. By focusing on this space, ZIVO is aligning itself with a growing movement toward more sustainable and health-focused solutions.
As ZIVO advances Zivolife™ toward commercialization, the company is expected to explore a range of applications across different sectors. In animal health, the products may be used to support immune function and overall wellness in livestock and companion animals. In human nutrition, they could serve as functional ingredients in dietary supplements and health-focused foods. Additionally, the potential for incorporation into broader functional ingredient markets opens up opportunities for partnerships with food and beverage companies seeking innovative, science-backed ingredients.
The agreement with Cyanotech represents a foundational step in realizing these opportunities. By securing a reliable manufacturing partner, ZIVO is positioning itself to move beyond the development stage and begin generating commercial value. This transition is often a defining moment for biotechnology companies, as it demonstrates the viability of their technology in real-world applications.
In conclusion, the manufacturing agreement between Zivo Bioscience and Cyanotech Corporation marks a pivotal advancement in ZIVO’s journey toward commercialization. By combining ZIVO’s proprietary algal technology with Cyanotech’s extensive experience and production capabilities, the partnership creates a strong platform for scaling Zivolife™ products across global markets. As demand for sustainable and innovative health solutions continues to grow, this collaboration positions both companies to play a meaningful role in shaping the future of algal-based therapeutics and nutrition.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit www.zivobioscience.com for more information.
About Cyanotech Corporation
Cyanotech Corporation is a world leader in microalgae technology with more than 40 years of experience producing high-value natural products derived from microalgae. Operating a 96-acre facility on the Kailua-Kona Coast of Hawaii, Cyanotech produces BioAstin® Hawaiian Astaxanthin® and Hawaiian Spirulina Pacifica® using patented, proprietary cultivation technology. All Cyanotech products are GRAS-certified and GMP-certified for dietary supplement use.
Source Link:https://www.businesswire.com/
